Update in Waldenstrom’s Macroglobulinemia - Juniper Publishers
Cancer Therapy & Oncology- Juniper Publishers Abstract Everolimus, an mTOR inhibitor, perifosine, an AKT inhibitor, enzastaurin, a phosphatidylinositide3 kinase/AKT inhibitor, panobinostat, a histone deacetylase inhibitor, ofatumumab, a third-generation anti-CD20 monoclonal antibody, and ibrutinib, a Bruton tyrosinekinase inhibitor, and newer drugs from known active subclasses, such as pomalidomide (immunomodulatory) and carfilzomib (proteasome inhibitor) arepromising drugs in various stages of study in WM. They may expand future treatment options. Abbreviations: WM: Waldenström’s Macroglobulinemia, LPC: Lymphoplasmacytic, MYD: Myeloid Differentiation Primary Response Gene, IgM: Immunoglobulin M, CNS: Central Nervous System, DLBCL: Diffuse Large B-Cell Lymphoma, ATM: Ataxia Telangiectasia-Mutated, BTK: Bruton’s Tyrosine Kinase, IRAK1: Interleukin-1 Receptor-Associated Kinases, WHIM: Warts Hypogamma globulinemia Infections Myelokathexis, WT: Wild-Type, ERK: Extrace